Navigation Links
IPC The Hospitalist Company, Inc. to Present at the 33rd Annual Deutsche Bank Health Care Conference
Date:4/28/2008

NORTH HOLLYWOOD, Calif., April 28 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national physician group practice company, announced today that Adam D. Singer, Chief Executive Officer, is scheduled to present on Tuesday, May 6, 2008 at the 33rd Annual Deutsche Bank Health Care Conference in Boston, MA. Jeffrey Taylor, President and Chief Operating Officer, will also be present at the conference.

Event: Deutsche Bank Health Care Conference

Date: Tuesday, May 6, 2008

Time: 1:30 p.m. ET

Place: The InterContinental Boston, Boston, MA

An audio Web cast of the Company's presentations will be available by visiting the investor relations section of IPC's Web site at http://www.hospitalist.com. A replay of the presentation will be available for 15 days.

About IPC The Hospitalist Company

IPC The Hospitalist Company, Inc. (Nasdaq: IPCM) is a leading national physician group practice company focused on the delivery of hospitalist medicine services. IPC's physicians and affiliated providers manage the care of hospitalized patients in coordination with primary care physicians and specialists. The Company provides its hospitalists with the comprehensive training, information technology, and management support systems necessary to improve the quality and reduce the cost of inpatient care in the facilities it serves. For more information, visit the IPC website at

SOURCE IPC The Hospitalist Company, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Benefits of hospitalist care confirmed in new study
2. Hospitalist Physicians Help Shorten Patient Stays
3. IPC The Hospitalist Company, Inc. Prices Initial Public Offering
4. IPC The Hospitalist Company, Inc. to Present at the 2008 UBS Global Healthcare Services Conference
5. IPC The Hospitalist Company, Inc. Announces Closing of IPO and Exercise of Underwriters Over-Allotment Option
6. IPC The Hospitalist Company, Inc. to Report Fourth Quarter and Year-End 2007 Financial Results
7. IPC The Hospitalist Company Announces Board of Director Member Changes
8. IPC The Hospitalist Company Reports Fourth Quarter and Full Year 2007 Results
9. IPC The Hospitalist Company Sets 2008 Annual Meeting Date
10. IPC The Hospitalist Company Added to Russell 2000 Index
11. IPC The Hospitalist Company, Inc. to Report First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:CAP Deeming Status Renewed 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 2Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 3Health News:Recovered Lyme Disease and US Track and Field Athlete Attends Movie Premiere of LymeLife 4Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 2Health News:Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions 3Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 2Health News:Exercise is safe, improves quality of life in patients with chronic heart failure 3Health News:New Prostate Cancer Drug May Hold Promise 2Health News:New Prostate Cancer Drug May Hold Promise 3
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 1EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 2EcoActive Surfaces Introduces OxiTitan VLR 3A New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors 55480 3Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 1Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 2Lakewood Amedex Inc to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains 4904 3New Fastrack Technology Improves Productivity 55477 1New Fastrack Technology Improves Productivity 55477 2New Fastrack Technology Improves Productivity 55477 3
Other Medicine Technology:Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 2Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 3Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 4Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 5Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 6Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 7Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 8Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response 9Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 2Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 3Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region 4